Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia

Stopped early · Phase 2

Conditions studied: Severe Aplastic Anemia

In brief

Patients with severe, refractory aplastic anemia have a severe, life threatening disease in their bone marrow. Refractory disease means that disease has come back or not responded after receiving one or more immunosuppressive treatments. High dose chemotherapy followed by bone marrow transplantation (BMT) has been used to treat blood diseases like aplastic anemia but complications from Graft vs Host disease (GVHD) and graft failure have limited the survival for those patients. Another study done here at Johns Hopkins has shown that in patients with other diseases (blood cancers) some immunosuppressive drugs given after the BMT has decreased how often patients had complications of GVHD and engraftment failure. This research is being done to find if this approach will help patients with aplastic anemia who have failed other treatments will have better outcomes.

Key facts

Study ID
NCT01383434
Run by
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
People needed
4
Starts
2011-06-01
Expected to finish
2014-08-01
Last updated by the study team
2016-10-13

Who can join

Age: 1 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.